Use of Rituximab for Refractory Cytopenias Associated With Autoimmune Lymphoproliferative Syndrome (ALPS)

Pediatric Blood and Cancer - United States
doi 10.1002/pbc.21965
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Rituximab–cyclophosphamide–dexamethasone Combination in the Management of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Response to Mercaptopurine for Refractory Autoimmune Cytopenias in Children

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

Autoimmune Lymphoproliferative Syndrome

2020English

Unmasking Evans Syndrome: T-Cell Phenotype and Apoptotic Response Reveal Autoimmune Lymphoproliferative Syndrome (ALPS)

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Erratum To: A FAS-ligand Variant Associated With Autoimmune Lymphoproliferative Syndrome in Cats

Mammalian Genome
Genetics
2017English

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus

Turkish Journal of Haematology
Hematology
2012English

Serum Sickness With Refractory Nephrotic Syndrome Following Treatment With Rituximab

CEN Case Reports
Nephrology
2018English

RASGRP1 Mutation in Autoimmune Lymphoproliferative Syndrome-Like Disease

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

American Journal of Hematology
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy